Revenio Group Corporation | Stock Exchange Release | February 21, 2025 at 16:00:00 EET The Board of Directors of Revenio Group Corporation has decided on a directed share issue without payment based o ...

Glaucoma affects vision and mental health, increasing anxiety and depression, which can worsen the disease. Open ...

We list the best Gantt chart software, to make it simple and easy to better visualize and manage progress when dealing with larges projects. Gantt chart software can be a powerful weapon in a ...

The prostaglandin evaluated in LL-BMT1 was bimatoprost, a well-established treatment for lowering intraocular pressure in glaucoma patients. With this milestone, MediPrint’s global patent ...

Agreement drives continued patient access to four important therapies in Japan and Korea Strengthens Essential Pharma and Clinigen's combined market presence in the JAPAC region Egham, UK - 6th ...

Aim To investigate the association between the extent of iridotrabecular contact and other quantitative anterior segment dimensions measured by swept-source optical coherence tomography (SS-OCT; CASIA ...

Blood pressure medications are usually taken for life. However, some people can stop taking them by addressing those underlying causes of high blood pressure (hypertension) that can be changed, such ...

which can occur and progress seemingly independent of elevated intraocular pressure, which is its most classically associated risk factor.” Solomon also said that he would take the results of ...

In the trial, people with diabetic macular edema who received Susvimo refilled every six months achieved noninferior improvements in vision compared with those receiving monthly 0.5-mg ranibizumab ...

(Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases ... authors to remove any pressure or influence on ...

QLS-111 added to latanoprost drove up to 3.6 mmHg greater reduction in IOP as compared to latanoprost alone DEDHAM, Mass., February 05, 2025--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage ...

Emerging research identifies neuroinflammation as a key driver of optic neuropathy in glaucoma, but the primary focus of glaucoma therapy today is decreasing the elevated intraocular pressure ...